Indian Fertility Experts Issue Stark Warning: New Non-Invasive Embryo Test Not Ready for IVF Clinics

Spread the Message

Read Time:3 Minute, 54 Second

Leading fertility organizations in India have urged clinics to halt routine use of a promising but unproven embryo genetic screening technology, citing high misdiagnosis risks that could harm IVF success rates. The caution, issued jointly by the Indian Society for Assisted Reproduction (ISAR), Indian Fertility Society (IFS), and Academy of Clinical Embryologists (ACE), comes amid rising demand for assisted reproduction amid India’s growing infertility challenges.

What is niPGT?

Non-invasive preimplantation genetic testing (niPGT), also known as non-invasive chromosomal screening (NICS), analyzes cell-free DNA fragments that embryos naturally shed into their culture medium during IVF lab growth, avoiding the need to biopsy cells from the embryo. Traditional preimplantation genetic testing for aneuploidy (PGT-A) requires removing 5-10 cells from the embryo’s outer layer (trophectoderm) on day 5 or 6, a technically demanding procedure with potential risks like embryo damage, estimated at around 5% in some studies. Proponents market niPGT as safer, simpler, and less invasive, fueling its uptake in Indian commercial labs despite limited validation.

Expert Panel’s Key Findings

A panel led by Dr. Deepak Modi from ICMR-National Institute for Research in Reproductive and Child Health reviewed global evidence on nearly 3,000 embryos tested via niPGT against biopsy-based methods, revealing significant inaccuracies including high false positives and false negatives. These errors could lead clinics to discard healthy embryos or transfer chromosomally abnormal ones, raising miscarriage risks or chances of disorders like Down syndrome. No robust data shows niPGT boosts implantation, pregnancy, or live birth rates, and extended day-6 culture often required may itself worsen outcomes per large studies.

Dr. Ameet Patki, ISAR President, stated: “The joint statement makes it clear that niPGT should not currently be used to select, rank, or discard embryos.” Dr. Modi elaborated: “niPGT appears to offer a simpler alternative… [but] there has been considerable uncertainty… about whether niPGT provides results accurate enough to guide life-altering decisions.”

Rising IVF Demand in India

India sees over 500,000 IVF cycles annually, driven by delayed childbearing, pollution, stress, and lifestyle factors, with success rates hovering at 30-40% per cycle for women under 35. Chromosomal issues cause up to 70% of IVF failures and recurrent miscarriages, making genetic screening appealing—yet only validated tools should guide decisions. ISAR, IFS, and ACE’s position statement, released around late 2025, marks India’s first unified patient-focused guidance on niPGT.

Global Research Context

Meta-analyses show niPGT’s sensitivity and specificity around 84-85%, with area under curve (AUC) of 0.91, promising but below biopsy PGT-A’s 95-99% reliability. Some studies report 78-92% concordance, hampered by maternal DNA contamination, mosaicism detection failures (where embryos have mixed normal/abnormal cells), and segmental errors. Optimistic trials like one using optimized workflows claim 91.3% accuracy, yet multi-center data flags inconsistencies. Experts note niPGT-A remains experimental in many regions, not a biopsy substitute.

Limitations and Counterarguments

While niPGT avoids biopsy risks, its diagnostic pitfalls—false positives discarding viable embryos, false negatives risking transfers—outweigh benefits without more data. Critics argue global studies vary by protocol, sample size, and lab standards; Indian experts emphasize local validation needs given diverse populations. Pro-niPGT voices highlight zero false-negative rates in refined setups and potential for AI/time-lapse integration, but panels counter no clinical outcome gains justify routine adoption. Ethical concerns include costs (adding ₹50,000-1,00,000 per cycle) and pressuring patients toward unproven tech.

Implications for Patients and Clinics

Couples should stick to proven PGT-A for high-risk cases like advanced maternal age (>35), recurrent losses, or donors, prioritizing euploid embryo transfers to lift success by 10-20%. Clinics offering niPGT must disclose limitations transparently, avoiding embryo selection based on it. This guidance protects India’s 1 in 6 infertile couples, promoting evidence-driven care amid booming ART clinics. Patients gain reassurance: focus on lifestyle, counseling, and validated tech yields better odds without hype.

Future Directions

Ongoing trials aim to refine niPGT via nanopore sequencing, extended culture tweaks, and contamination filters, potentially enabling routine use in 2-5 years. Indian societies call for research investment, standardized protocols, and regulatory oversight per ICMR guidelines. Until then, cautious optimism prevails—innovation serves patients only when proven safe.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.